Late-Breaking Abstracts

LBA 01

Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920


Purpose/Objective(s): The combination of radiotherapy (RT)/cetuximab has demonstrated superiority over RT alone for locally advanced non-operative SCCHN. We performed a definitive randomized trial to test this hypothesis in completely resected, intermediate-risk SCCHN.

Materials/Methods: Enrolled patients had SCCHN of the oral cavity, oropharynx or larynx (hypopharynx was excluded); complete resection with negative margins and no evidence of nodal extracapsular spread; but one or more risk factors warranting postoperative RT. Patients were randomized 1:1 to IMRT (60-66 Gy) with cetuximab (C) (loading dose 400 mg/m2 pre-RT plus weekly 250 mg/m2 up to 11 total doses) (RT+C) or without C (RT). Patients were stratified by tumor site/ HPV status, clinical T-stage, EGFR expression level, and use of daily IGR T. The primary hypothesis was that RT+C would achieve superior overall survival (OS) in eligible patients. The trial was designed to detect a hazard ratio of 0.74 with 80% power, and 1-sided alpha of 0.025 (372 OS events, target enrollment of 700 patients). Disease-free-survival (DFS) and toxicity were secondary endpoints. Late toxicity was defined as >90 days after start of RT. OS and DFS between arms were compared via stratified log-rank test; toxicity was compared via Fisher’s exact test. Locoregional failure was a tertiary/exploratory endpoint.

Results: The study enrolled 702 pts from 11/2009-3/2018; 627 were randomized, and 577 were eligible (287 RT and 290 RT+C). Most patients (64%) had oral cavity cancer, and 52% had clinical AJCCv6 stage IV (M0) cancer; a large majority (84.6%) had high EGFR expression. Due to substantially lower than expected event (death) rates, the protocol was amended to perform a time-driven analysis with data as of 06/05/2023 (184 OS events). At a median follow-up of 7.2 years, OS was not significantly improved, but DFS was (see table). Grade 3-4 acute toxicity rates were 70.3% (RT+C) versus 39.7% (RT), (p<0.0001), mostly related to skin and/or mucosal effects. Late Grade ≥3 toxicity rate was 33.2% (RT+C) versus 29.0% (RT) (p=0.3101). There were no Grade 5 toxicities in either arm.

Conclusion: Radiotherapy + cetuximab (RT+C) did not show OS superiority but significantly improved DFS, compared to RT alone for patients with resected, intermediate-risk SCCHN. Acute but not late toxicity was increased with RT+C. RT+C may be considered for this patient population, but it will be critical to identify subgroups achieving benefit from this combined-modality therapy.

LBA01 – Table 1

<table>
<thead>
<tr>
<th>5-year rates (%) [95% CI]</th>
<th>HR [95% CI] *</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS</td>
<td>68.7 [63.1, 74.3]</td>
<td>76.5 [71.4, 81.6]</td>
</tr>
<tr>
<td>DFS</td>
<td>63.6 [57.8, 69.3]</td>
<td>71.7 [66.3, 77.1]</td>
</tr>
<tr>
<td>LRF</td>
<td>25.0 [20.0, 30.3]</td>
<td>19.3 [14.9, 24.3]</td>
</tr>
</tbody>
</table>

*Stratified (cause-specific) Cox models; 5 OS; 6 DFS; 7 LRF

Acknowledgements: Support from NIH/NCI including grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Statistical Center), U24CA196067 (NRG Biospecimen bank); and from Eli Lilly Inc.

**LBA 02**

**Randomized Controlled Trial of Hypofractionated vs. Normo-fractionated Accelerated Radiation Therapy with or without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO)**

S.M. Bentzen,1 E. Rosenblatt,2 T. Gupta,3 J.P. Agarwal,3 S. Ghosh Laskar,3 S. Bhasker,2 A.A. Jacinto,2 P. De Marchi,4 M. Nagarajan,5 K. Jabeen,2 S. Binia,2 Y. Chansilpa,2 M. Napoles,7 S. Aguiar,11 O. Goloubeva,11 E. Zubizarreta,8 K. Hopkins, and M. Abdel-Wahab1

**Purpose/Objective(s):** HYPNO, a multi-center, two-arm, unblinded phase III trial, tested definitive hypofractionated (HFX) vs. normofractionated (NFX) accelerated RT +cisplatin for locally advanced HNSCC. HYPNO opened in 12 centers in 10 low- and middle-income countries. We hypothesized HFX (55 Gy, 20F, 5F/wk over 4 weeks) is non-inferior to NFX (66 Gy, 33F, 6F/wk over 5.5 weeks) + weekly cisplatin with a non-inferiority margin, Δ, chosen as an absolute difference of 10% at 3 years for the coprimary endpoints of loco-regional control (LRC) and Grade 3+ late adverse events (LAE). Chosen Δ corresponds to critical hazard ratios of 1.31 (LRC) and 1.5 (LAE).

**Materials/Methods:** 792 pts. were centrally randomized Mar 2014 to Feb 2020, 395 to HFX, 397 to NFX. Accrual closed, with all outcome data still blinded, with 792 of a planned 836 pts. (94.7%) enrolled, in part due to the emerging COVID-19 pandemic, in part due to accrual leveling off. Chemoradia-tion, prescribed before randomization, consisted of i.v. cisplatin 35 mg/m² weekly during RT, 4 cycles in HFX arm, 5 in NFX arm. Stratification factors (distribution): Performance status 0-1 v. 2 (3.7%), Chemotherapy n. y (75.8%); Tumor subsite: oral cavity (8.5%) v. oropharynx (50.5%) v. hypopharynx (13.5%) v. larynx (24.5%) v. other (3.0%), and institution. Enrollment was 86.9% males; 38.1% current and 39.3% former smokers; T3-4 (72.7%); Tumor subsite: oral cavity (8.5%) v. oropharynx (50.5%) v. hypopharynx (13.5%) v. larynx (24.5%) v. other (3.0%), and institution. Enrollees (75.8%); Tumor subsite: oral cavity (8.5%) v. oropharynx (50.5%) v. hypopharynx (13.5%) v. larynx (24.5%) v. other (3.0%), and institution. Enrollees (75.8%); Tumor subsite: oral cavity (8.5%) v. oropharynx (50.5%) v. hypopharynx (13.5%) v. larynx (24.5%) v. other (3.0%), and institution. Enrollees (75.8%); Tumor subsite: oral cavity (8.5%) v. oropharynx (50.5%) v. hypopharynx (13.5%) v. larynx (24.5%) v. other (3.0%), and institution.

**Prospective end points**: 5-year outcomes were remarkably similar with an absolute difference of 10% at 3 years for the coprimary endpoints of LRC and Grade 3+ late adverse events (LAE). Chosen Δ corresponds to critical hazard ratios of 1.31 (LRC) and 1.5 (LAE).

**Results:** Results: 3-year outcomes (see table). HFX was non-inferior for the coprimary endpoints. For LRC, HR=1.098, 95% CI (0.929, 1.298), non-inferiority p=0.041. For LAE G3+, HR=0.926, 95% CI (0.684, 1.253), non-inferiority p=0.004. Regarding early adverse events, max grade of mucositis was 3+ in 190/373 (50.9%) of cases after HFX and 208/380 (54.7%) after NFX, Fisher’s Exact Test p=0.007.

**Conclusion:** HYPNO shows hypofractionated accelerated RT is non-inferior to the 6-weeks-a-week schedule with respect to both loco-regional tumor control and Grade 3+ late adverse events. In addition to passing the non-inferiority test, the 3-year outcomes were remarkably similar with an absolute difference of <1.5% between the two arms. This result is potentially practice changing. Treating in 20 fractions instead of 33 is both resource sparing and more convenient to patients. HYPNO is, to the best of our knowledge, the largest randomized controlled trial with this level of complexity conducted in the setting of low- and middle-income countries.

<table>
<thead>
<tr>
<th></th>
<th>OS</th>
<th>PFS</th>
<th>LRC</th>
<th>Late G3+ AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFX</td>
<td>514±27.7%</td>
<td>44.0±2.6%</td>
<td>50.7±2.7%</td>
<td>18.8±2.4%</td>
</tr>
<tr>
<td>NFX</td>
<td>55.5±2.6%</td>
<td>45.3±2.6%</td>
<td>51.2±2.7%</td>
<td>20.2±2.4%</td>
</tr>
<tr>
<td>P-value</td>
<td>0.62</td>
<td>0.42</td>
<td>0.40</td>
<td>0.68</td>
</tr>
</tbody>
</table>


**LBA 03**

**5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer**

N. van As,1 A. Tree,1 J. Patel,3 P. Ostler,1 H. Van Der Voet,1 D.A. Loblaw,4 W. Chu,2 D. Ford,1 S. Tolan,3 S. Jain,5 J.G. Armstrong10,12, P. Camilleri,12 K. Kancherla,1 J. Frew,8 A. Chan,2 O. Naismith,7 G. Manning,8 S. Brown,9 C. Griffin,11 and E. Hall12

**Purpose/Objective(s):** External beam radiotherapy (EBRT) is a curative treatment for Localized Prostate Cancer (LPCa). Large randomized controlled trials (RCTs) have shown moderately hypofractionated regimens (2.5–3 Gy/fraction) are non-inferior to 2Gy/f fraction regimens. PACE-B aims to demonstrate non-inferiority of SBRT compared to conventionally or moderately hypo fractionated regimens for biochemical and/or clinical failure (BCF).

**Materials/Methods:** PACE (NCT01584238) is an international phase III open-label multiple-cohort RCT. Men with LPCa, stage T1-T2, ≤ Gleason 3+4, PSA ≤ 20 ng/mL, unsuitable for surgery or preferring EBRT, were eligible. Participants (pts) were randomized (1:1) to SBRT (36.25 Gy / 5 in 1-2 weeks (wks)) or control radiotherapy (CRT) (78 Gy / 39 f over 7.5 wks, or 62 Gy / 20 f in 4 wks) to the planning target volume. Androgen depriv-ation therapy was not permitted. The primary endpoint was freedom from biochemical (BF)/clinical (CF) failure. BF is based on PSA rises, commencement of ADT or date of orchietomy and CF is based on local recurrence, nodal recurrence, distant metastases and death from prostate cancer. 858 pts were needed to rule out 6% inferiority (80% power, one-sided alpha 5%) assuming 85% event-free rate with CRT, corresponding to a critical hazard ratio of (HR) of 1.45. Analysis was done by intention to treat.

**Results:** Results: 874 pts were randomized from 38 centers (n=441 (CRT) and n=433 (SBRT)) between 08/2012 and 01/2018. Baseline characteristics were well balanced across CRT and SBRT groups: median age 69.8 years (IQR 65.4,74.0); median PSA ng/mL (IQR): 8.1 (6.3,11) vs 7.9 (5.5,10.9); NCCN risk group 9.3% low, 90.7% intermediate. With median follow-up of 73.1 months (IQR 62.6, 84.0), 5-year BCF event free-rate (95% CI) was 94.6% (91.9% - 96.4%) for CRT and SBRT groups respectively. SBRT was non inferior to CRT with an adjusted HR (90% CI) = 0.74 (0.47 - 1.17), p-value for non-inferiority=0.007. The estimated absolute differences in the proportion of patients event free in the SBRT group compared with that in the CRT group at 5 years was: 1.36% (90% CI: 0.87 - 2.80). At 5 years, RTOG grade 2 or worse (G2+) genitourinary toxicity was seen in 3.2% (1/348) pts who received CRT and 5.5% (20/363) pts who received SBRT (p=0.14); RTOG G2+ gastrointestinal toxicity was seen in 1/348 receiving CRT and 1/363 receiving SBRT (p=0.99).
LBA 04
Primary Endpoint Results of NRG CC003: Phase II/III Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC)

V. Gondi,1 S. Pugh,2 M.P. Mehta,3 J.S. Wefel,4 W.A. Tome,5 A. Sun,6 G.M. Videtic,7 B.H. Lok,8 H.A. Yoon,9 J.H. Heinzerling,7 II A.S. DeNittis,11 R.C. McGarry,12 K. Devisetty,13 V. Kundapur,14 A.J. Wu,15 R. Paulus,16 and L.A. Kachnic17
Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville IL; 2NRG Oncology Statistics and Data Management Center, Philadelphia, PA; 3Florida International University, Herbert Wertheim College of Medicine, Miami, FL; 4The University of Texas MD Anderson Cancer Center, Houston, TX; 5Institute for Onco-Physics, Albert Einstein College of Medicine, Bronx, NY; 6Radiation Medicine Program, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada; 7Department of Radiation Oncology, Tausig Cancer Institute, Cleveland Clinic, Cleveland, OH; 8Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; 9Cancer Care Specialists of Illinois, Decatur, IL; 10Levein Cancer Institute, Atrium Health and Southeast Radiation Oncology Group, Charlotte, NC; 11Lankenaan Institute for Medical Research, Wynnewood, PA; 12University of Kentucky, Lexington, KY; 13Wayne State University/McLaren Cancer Institute, Flint, MI; 14Saskatoon Cancer Centre, Saskatoon, SK, Canada; 15Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; 16NRG Oncology Statistics and Data Management Center, Philadelphia, PA; 17Columbia University, New York, NY

Purpose/Objective(s): Prior randomized trials have demonstrated neurocognitive function (NCF) benefits of HA during whole-brain radiotherapy for non-SCLC brain metastases. NRG CC003 sought to evaluate whether HA confers similar neuroprotection and non-inferior intracranial relapse (ICR) risk following PCI for SCLC.

Materials/Methods: SCLC patients (pts) were stratified by age, stage and planned memantine use, and randomized to PCI or HA-PCI (25Gy in 10 fractions). Standardized NCF tests of Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Tests (TMT), and Controlled Oral Word Association (COWA) were performed at baseline, 3, 6, 12, 18 and 24 months (mos). The primary endpoints were 12-mo ICR (phase II) and 6-mo HVLT-R Delayed Recall (DR) failure, defined as decline using the reliable change index (phase III). To detect a 14.5% reduction in 6-mo HVLT-DR failure, 196 analyzable pts were required for 80% power and one-sided a=0.05. Phase III sample size was increased to 392 pts for non-compliance and death. Secondary endpoints were first failure in any NCF test and failure in other NCF tests. NCF failure was analyzed using Fisher’s exact test and mixed effects models. Cumulative incidence estimated time to NCF failure (death without NCF failure was competing risk); between-arm comparison tested using Cox proportional hazards model.

Results: From 12/2015-6/2022, 392 pts were randomized; study closed from 10/2017-7/72020 for phase II/III analysis. Median age was 64.70% had limited stage; 47% used memantine. Median follow-up was 14.9 mos (all pts) and 24 mos (alive pts). Grade≥3 toxicity did not differ. HA-PCI had non-inferior 12-mo ICR rate (PCI 14.8% vs. HA-PCI 14.2%, p<0.0001 to rule out inferiority). 6-mo HVLT-R DR deterioration was not significant (PCI 30.0% vs. HA-PCI 26.0%, p=0.31). Addition of HA to PCI prevented NCF failure (adjusted HR=0.77, 95% confidence interval (CI): 0.61-0.98, p=0.03). Memantine use trended to increased NCF failure (adjusted HR=1.26, 95% CI: 0.99-1.59, p=0.062); test for interaction between HA and memantine use was non-significant. HA-PCI arm had higher COWA scores at baseline (mean: PCI 31.9 vs. HA-PCI 34.4, p=0.019) and exhibited greater deterioration in COWA over time (estimate -0.259, p=0.042). There were no differences in overall survival (adjusted HR=0.83, 95% CI: 0.63-1.09, p=0.19).

Conclusion: While the study did not meet its HVLT-R DR failure primary endpoint, HA during PCI prevents NCF failure with non-inferior ICR risk and similar survival. The NCF benefit of HA was independent of non-significant higher NCF failure risk with memantine use. Worse verbal word fluency, assessed using COWA, following HA-PCI requires further investigation given baseline between-arm imbalance in COWA scores. Supported by grants UG1CA189867 (NCORP) and U24CA180803 (IBOC) from the NCI.


LBA 05
Patient-Reported and Toxicity Results from the FABREC Study: A Multicenter Randomized Trial of Hypofractionated vs. Conventionally-Fractionated Postmastectomy Radiation Therapy after Implant-Based Reconstruction

J.S. Wong,1 H. Uno,2 A. Tramontano,2 C. Pellegrini,7 J.R. Bellon,1 M.D. Cheney,1 P.H. Hardenbergh,4 A.Y. Ho,5 K.C. Horst,5 and J.N. Kim,7

Conclusion: Five-year BCF free rates are high in PACE-B participants. After median follow-up of six years, five-motion-SBRT is non-inferior to CRT for BCF. SBRT reduces pts attendances, shortens treatment time and 5 fraction SBRT should be a new standard of care for pts with low/favourable intermediate risk LPCa.

Author Disclosure: N. van As: Grant/research funding; Accuray, Varian. Honoraria; Accuray, Varian. Professor of Precision Prostate Radiotherapy; The Institute of Cancer Research. Medical Director; The Royal Marsden. A. Tree: Grant/research funding; Elekta, Accuray, Varian. Honoraria; Elekta, Janssen. Travel expenses; Elekta. Salary support; Elekta. Committee member; UK SABR consortium. Lead editor for GU at the red journal, which is financially compensated; IJROBP. I receive no direct compensation but my employer receives financially compensated; IJROBP. I receive no direct compensation but my employer receives financially compensated; IJROBP. I receive no direct compensation but my employer receives financially compensated; IJROBP. I receive no direct compensation but my employer receives financially compensated; IJROBP. I receive no direct compensation but my employer receives financially compensated; IJROBP.
Purpose/Objective(s): This randomized trial of fractionation after breast reconstruction (FABREC) sought to compare quality-of-life (QOL) and clinical outcomes of hypofractionated (HF) vs. conventionally-fractionated (CF) postmastectomy radiation therapy (PMRT) in the setting of immediate prosthetic reconstruction.

Materials/Methods: Between 3/2018 and 11/2021, 400 patients at 18 centers with Stage 0-III breast cancer and immediate placement of tissue expander (TE) or implant (I) after mastectomy were randomized 1:1 to HF (25.0 Gy/10 fractions to the chest wall (CW), with or without axillary/supraclavicular or CF photon PMRT. Respective doses in the two arms were 42.56 Gy/16 fractions to the chest wall (CW), with or without axillary/supraclavicular lymph node (LN) radiation (39.9 Gy/15 fractions) and 50 Gy in 25 fractions to the chest wall (CW), with or without axillary/supraclavicular or CF photon PMRT. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAT-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.

Results: Median follow-up for the 385 patients analyzed was 31.8 months (range, 6.9-54.4); median age was 47.0 years (range, 23-79). Preoperative chemotherapy was used in 67.8% and preoperative endocrine therapy (ET) in 21.5% of the cohort. There were 16 distant (8 in each arm) and 2 local-regional (1 in each arm) recurrences. CW toxicity was defined as any grade ≥3 adverse event (CTCAE) after PMRT initiation. Patients were censored at study withdrawal or at diagnosis of distant recurrence. Participants completed QOL instruments (FACT-B, BREAST-Q, Lymph-ICF) at baseline, 6, 12 and 18-months from PMRT initiation. Questions regarding financial burden were included with the 6-month survey. Primary endpoint of the study was improvement in the Physical Well-Being (PWB) domain of FACT-B at 6 months with pre-specified stratification by age (younger than 45 vs. 45 years or older). QOL scores were compared using Student’s t-test.
**Conclusion:** In patients with high-risk BCR and prior RT, both enza + LA and enza mono demonstrated a clinically meaningful improvement in MFS vs placebo + LA. In patients without prior RT, the number of MFS events was too low to draw any conclusions. If approved, enza combination therapy may represent a new standard of care for patients with high-risk BCR and prior RT.

**LBA 06 – Table 1. MFS per BICR**

<table>
<thead>
<tr>
<th>Prior RT (yes)</th>
<th>Enza + LA (n=355)</th>
<th>Placebo + LA (n=358)</th>
<th>Enza mono (n=355)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>265</td>
<td>283</td>
<td>256</td>
</tr>
<tr>
<td>Events</td>
<td>37</td>
<td>76</td>
<td>43</td>
</tr>
<tr>
<td>Median (95% CI, months)</td>
<td>NR (NR—NR)</td>
<td>85.1 (80.1—NR)</td>
<td>NR (NR—NR)</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.45 (0.30–0.66)</td>
<td>–</td>
<td>0.57 (0.39–0.82)</td>
</tr>
<tr>
<td>Nominal p-value</td>
<td>&lt;0.0001</td>
<td>–</td>
<td>0.0025</td>
</tr>
</tbody>
</table>

**Prior RT (no)**

| n              | 90                | 75                   | 99               |
| Events         | 8                 | 16                   | 20               |
| Median (95% CI, months) | NR (NR—NR)       | NR (NR—NR)       | NR (NR—NR)       |
| HR (95% CI)    | 0.37 (0.16–0.87)  | –                    | 0.93 (0.48–1.79) |
| Nominal p-value| 0.0169            | –                    | 0.8259           |

NR, not reached
Clinical trial registration number: NCT02319837.

**Purpose/Objective(s):** Although SRT is preferred for limited brain metastases from most histologies, WBRT has remained the standard of care for patients with SCLC. It remains unclear whether the benefit of WBRT to SRT for the intracerebral tumor control outweighs the potential neurocognitive risks in SCLC patients.

**Materials/Methods:** This pilot-trial is a single-center prospective, randomized, two-arm Phase II study. The primary endpoint is neurocognition after cerebral irradiation in SCLC patients treated with WBRT or SRT (radiosurgery (SRS) with 20 Gy or 18 Gy or hypofractionated SRT with 30 Gy in 5 Gy fractions for lesions >3 cm) defined as a drop of at least 5 points from baseline in Hopkins Verbal Learning Test—Revised (HVLT-R) total recall subscale at 3 months after baseline. Eligible patients had histologically confirmed SCLC, MRI-confirmed cerebral metastasis (not resected, maximum number of 10), Karnofsky performance score >50 and no prior irradiation to the brain. Patients were randomly assigned (1:1) to either SRT or WBRT. Secondary endpoints included survival parameters, quality of life, toxicity and neurocognitive assessments.

**Results:** 36 patients were randomized to either WBRT or SRT. The modified intention-to-treat (mITT) set included all randomized patients, who started study treatment with WBRT (n=25) or SRT (n=26). Prior to imputation, the primary endpoint was achieved in 77% (n=2) of patients in the SRT group and 24.0% (n=6) of patients in the WBRT group (mITT set). After multiple imputation via predictive mean matching, the primary endpoint was analyzed using the Cochran–Mantel–Haenszel test stratified for time of appearance (p=0.0723). For preliminary OS analysis in the mITT set, data up to 6 months were considered. Patients not having reached the endpoint were censored at 181 days. There was no significant difference in survival probability between treatment groups (p=0.36). Median time to death (at 6 months) was 124.0 (Q1 43.0–Q3 139.5) days in the SRT group and 131.0 (Q1 107.0–Q3 150.0) in the WBRT group.

**Conclusion:** SCLC patients in the WBRT group were at a greater risk of a significant decline in neurocognitive function 3 months after baseline compared with the SRT group. SRT should be considered one of the standards of care for patients with brain metastases from SCLC.


**LBA 07**

**Stereotactic Radiotherapy vs. Whole Brain Radiation Therapy for Patients with 1-10 Brain Metastases from Small Cell Lung Cancer: Results of the Randomized ENCEPHALON (ARO 2018-9) Trial**

D. Bernhardt,1 R. El Shafei,2,4,5 M. Thomas,1 F. Bozorgmehr,6 A. Schiele,2 D. Schmitt,2,4 T. Welzel,4 P. Thalmann,4 A. Paul,4 L. König,4 K. Lang,4 S. Adebeg,4 S. Höne,4 F. Weykamp,5 P. Vollmuth,6 A. Lentz-Homberg,6 C. Jaekel,4 U. Nestle,4,5,6 M. Kieser,6 J. Debus,4,5,6 and S. Rieken.7

1Department of Radiation Oncology, Heidelberg University Hospital & Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Heidelberg, Germany, 2Heidelberg University Hospital, Dept. of Radiation Oncology, Heidelberg, Germany, 3University Medical Center Göttingen (UMG), Dept. of Radiation Oncology, Göttingen, Germany, 4Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany, 5German Center for Lung Research (DZL), Heidelberg, Germany, 6Heidelberg University Hospital, Institute of Medical Biometry, Heidelberg, Germany, 7University Medical Center of Gießen and Marburg (UKGM), Dept. of Radiation Oncology.

Marburg, Germany, 8Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, 9University Hospital Heidelberg, Department of Neuroradiology, Heidelberg, Germany, 10University Hospital Heidelberg, Department of Radiation Oncology, INF 400, Heidelberg, Germany, 11Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 12Klinikum Maria Hilf, Department of Radiation Oncology, Moenchengladbach, Germany, 13Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany, 14CCU Translational Radiation Oncology, German Cancer Research Center (DKFZ), National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany.
LBA 08
Acute Toxicity and Efficiency Outcomes in the DARTBOARD Randomized Trial of Daily Adaptive Radiotherapy for Head and Neck Squamous Cell Carcinoma

D.J. Sher,1 V. Avkshtol,2 M.H. Lin,1 R. Hughes,3 J. Wang,4 M. Dohopoulos,5 J. Van Pelt,6 C.Y. Liao,7 and D.H. Moon1; 1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 2University of Texas Southwestern Department of Radiation Oncology, Dallas, TX, 3University of Texas Southwestern Medical Center, Dallas, TX, 4UT Southwestern Medical Center, Dallas, TX

Purpose/Objective(s): The clinical utility of adaptive radiotherapy (ART) for head and neck (H&N) squamous cell carcinoma (SqCC) remains poorly defined. Online daily ART (DART) promises both anatomic adaptation and planning target volume (PTV) reduction by developing a unique plan based on the anatomy at each fraction, rendering interfraction setup error negligible. In this prospective trial using CBCT-based ART, patients with H&N SCC undergoing definitive RT (+/- chemotherapy, CRT) were randomized to daily online DART with reduced PTV margins (DART arm) or standard PTV margins without ART (IGRT arm).

Materials/Methods: Eligibility criteria included a diagnosis of oropharynx, larynx, or hypopharynx SqCC receiving definitive RT or CRT. All individuals received involved nodal radiotherapy (INRT) per a previous institutional study. The gross tumor volume (GTV) received 70 Gy, the primary clinical target volume (CTV) and suspicious nodes received 63 Gy, and nodes on the same level as nodal GTV or identified by an artificial intelligence (AI) algorithm received 56 Gy. The PTV margin in the DART arm was 1mm (2mm S/I), compared to 5mm in the IGRT arm. A H&N radiation oncologist adapted each DART fraction. The primary endpoint was patient-reported xerostomia at one year, requiring enrollment of 50 patients, stratified by oropharynx versus larynx/hypopharynx site. Patients completed the EORTC QLQ30/HN35, MDADI, and the Xerostomia Questionnaire (XQ) patient-reported outcome (PRO) instruments at baseline/1/3/6/12 months after treatment.

Results: Fifty patients were enrolled (26 IGRT, 24 DART). The cohort consisted of 38 oropharynx and 12 larynx/hypopharynx patients, with AJCC 7th stage I-II (n=4), III (n=10), and IVa/B (n=36). Forty-six patients (92%) were treated with CRT. The mean ipsilateral (16.0 vs. 11.5 Gy, p=0.02) parotid gland and ipsilateral (56.3 vs. 42.2 Gy, p<0.01) and contralateral (36.5 vs. 28.2 Gy, p=0.04) submandibular gland doses were significantly lower with DART. Swallowing QoR doses were not significantly different. The mean total patient in-room, recontouring, and physician at-console times were 33 (SD 5.3), 126 (SD 3.4), and 22 (SD 4.4) minutes per adaptive fraction, respectively. There was significantly less G2+ dermatitis in the DART arm (Grade 2+ 31% vs 8%, p=0.05) but not mucositis or dysphagia. No PRO differences were noted at one month, but at three months, trends favored reduced xerostomia with DART (XQ 43.1 vs. 31.2, p=0.02; for oropharynx patients, XQ 45 vs. 28.6, p=0.11). At a median follow-up of 7 months, one in-field, one out-of-field, and two distant recurrences were observed.

Conclusion: Online DART for H&N SqCC may improve physician- and patient-reported acute toxicity profiles, albeit with increased resource utilization. Additional evidence and follow-up is needed to understand the potential benefits and limitations of this paradigm.


LBA 09
Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER-Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial

S.P. David,1 S. Siva,2 M. Bressel,4 J. Tan,4 G.G. Hanna,3 R.K. Alomran,6 E. Yip,7 C. Morton,7 M. Edmonds,7 and M. White8; 1Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; 2Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; 3Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC, Australia; 4Peter MacCallum Cancer Centre, Melbourne, Australia; 5Patrick G Johnston Centre for Cancer Research, Belfast, United Kingdom; 6Department of Radiation Oncology, Comprehensive Cancer Centre, King Fahad Medical City, Riyadh, Saudi Arabia; 7Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; 8Monash Medical Centre, Melbourne, Australia

Purpose/Objective(s): To assess if stereotactic ablative body radiotherapy (SABR) for oligoprogressive luminal (ER positive, Her-2 negative) advanced breast cancer could delay a change in combination CDK 4/6 inhibitor and an aromatase inhibitor therapy (CDK 4/6 + AI) by ≥ 6 months in > 25% of patients. Herein we report the primary outcome.

Materials/Methods: AVATAR (ACTRN 12620001212943) enrolled eligible patients with advanced luminal breast cancer who received first or second line systemic treatment in the metastatic setting with a CDK 4/6 + AI for ≥ 6 months. Patients required an ECOG performance status of 0-2 and 1-5 extracranial oligoprogressing lesions amenable to SABR. Patients who had chemotherapy for metastatic disease, leptomeningeal disease, or prior radiotherapy to an oligoprogressing lesion planned for SABR were excluded. At subsequent progression, further SABR was permitted to delay a change in systemic therapy. The primary endpoint was event free survival (EFS) defined as a time to change in systemic therapy after SABR, any progression within 6 months or in > 3 lesions. Secondary endpoints were progression free survival (PFS), overall survival (OS), treatment related toxicity and modified progression free survival (mPFS) defined as progression not amenable to further SABR at any time.

Results: 32 patients were recruited (Aug 2020 – Nov 2022), with a median follow-up of 15.8 months. The number of patients with 1, 2, 3, or 4 sites of oligoprogression at baseline was 13 (41%), 10(31%), 7 (22), and 2 (6%), respectively. The most common sites of oligoprogression were bone (44%), and nodal (11%). The most common SABR doses were 20 Gy /1 fraction and 24 Gy/2 fractions. The null hypothesis was rejected, with 47% (95% CI: 29-65) of patients remaining event free for ≥ 6 months. The median mPFS was 10.4 months (95% CI: 4.1-not reached) with 46% (95% CI: 27-63) remaining unchanged on systemic therapy for 12 months. Median PFS was 5.2 months (95% CI: 3.1-6.8), with 10/30 (33%) progressions suitable for a second course of SABR for oligoprogression to further delay systemic therapy change. 17 (53%) patients had no treatment related toxicity. 13 (40%) and 2 (13%) patients experienced grade 1 or 2 treatment related toxicities respectively, with no grade 3 or higher toxicities reported.

Conclusion: This is the first prospective trial investigating SABR as a strategy to maintain CDK 4/6 + AI in patients with oligoprogressive luminal breast cancer. This approach was well tolerated, with a higher than anticipated median time to change in systemic therapy of 10.4 months, and 46% of patients maintained on a CDK 4/6 + AI for 12 months. These findings suggest that patients with oligoprogressive luminal breast cancer should be considered for SABR in lieu of a change in systemic therapy.

Author Disclosure: S.P. David: Grant/research funding; Roche Genentech. S. Siva: payment to institution; Refluxion Medical Systems. Payment to institution; AstraZeneca, Varian Medical Systems, volunteer role for advisory of the board; Radiosurgery Society (RSS). advisory role; ART committee of IASLC. M. Bressel: Honoraria; Sir Peter MacCallum Department of Oncology, University of Melbourne. Prov- vide advice; Australia New Zealand Gynaecological Oncology group. J. Tan: None. G.G. Hanna: Travel expenses; MSD. Compensation/Payment; AstraZeneca. R.K. Alomran: Honoraria; MESTRO. E. Yip: None. C. Morton: Management advisory consultant; Open Advisory. M. Edmonds: None. M. White: Honoraria; Pfizer, Gilead. Provide advice; Breast Cancer Network Australia.
**LBA 10**

**Partial Breast Radiotherapy for Women with Early Breast Cancer: 10-Year Outcomes from IMPORT LOW (CRUK/06/003)**

A. Kirby,1,2 C. Griffin,1 L. Finneran,3 M. Sydenham,4 A. Alhasso,4 A.M. Brutn,5 H. Chan,6 M. Jef ford,5 E. Sawyer,7 I. Syndikus,8 Y.M. Tsang,9 D. Wheatley,11 J. Yarnold,12 C. Coles,1,13 and J. Bliss3

**Purpose/Objective(s):** IMPORT LOW is a randomized, multi-center phase III trial testing partial breast radiotherapy (RT) using intensity modulated RT in women with early-stage breast cancer at lower than average risk of ipsilateral breast tumor relapse (IBTR). Five-year results concluded non-inferiority for reduced-dose & partial-breast RT with similar normal tissue effects (reduced for breast appearance & hardness as reported by patients; Lancet, 2017). Here we report outcomes after 10 years.

**Materials/Methods:** Women age ≥50 who had breast conservation surgery, for invasive breast cancer (excluding classical lobular carcinoma) ≥1-2 (≤3cm) N0-1, any grade, with microscopic margins of ≥2 mm, were eligible. Patients were randomized (1:1:1) to 40Gy/15F to whole breast (control); 36Gy/15F to whole breast & 40Gy/15Fy to partial breast (reduced-dose); or 40Gy/15F to partial breast (partial-breast). The primary endpoint is IBTR. 10-year clinician assessed adverse effects were collected. Patient assessments were not recorded at 10 years. Efficacy analysis was intention to treat.

**Results:** 2016 patients were recruited from 05/2007 to 09/2010 from 30 UK RT centers (674 control, 669 reduced-dose, 669 partial-breast). Median age was 63 years (IQR 57-68): 42%, 48% & 10% of patients had tumors that were grade 1, 2 & 3 respectively; 3% were node positive. Median follow-up is 121 (IQR 120-124) months. 10-year follow-up forms were received for 518, 520 & 510 whole, reduced & partial groups respectively. 10-year rates of IBTR are 2.8% (95%CI 1.8-4.5), 1.9% (1.1-3.4) & 2.8% (1.7-4.5) in the whole-breast, reduced-dose & partial-breast groups respectively. Absolute treatment differences in IBTR compared with control for reduced-dose is -1.02% (95%CI -1.97, 0.96) & -0.02% (-1.38, 2.58) for partial-breast. 10-year overall survival rates are 87.8% (95%CI 84.9, 90.1), 87.2% (84.3, 89.6) & 90.3% (87.7, 92.4) for control, reduced-dose & partial-breast groups respectively. Clinician assessed adverse effects indicate low rates of moderate/marked events at 10 years (Table 1).

**Conclusion:** At 10 years, rates of IBTR & clinician assessed moderate/ marked adverse effects remain very low across all treatment groups demonstrating that reduced-dose & partial-breast RT are safe & effective RT techniques.

**LBA 11**

**Early Results of a Phase I Pre-Operative Single Fraction Ablative Trial for Early Stage Breast Cancer**

A.S. Rahimi,1 M. Leitch,2 P.G. Alluri,1 D. Farr,2 M. Arbab,3 S. Seiler,4 D.W.N. Kim,7 R. Wooldridge,8 N. Unni,9 C.R. Nwachukwu,1 I. Patel,1 Y. Zhang,1 D.D.M. Parsons,1 A. Nguyen,1 H. Morgan,2 H.L. McArthur,1 S. Sahoo,1 and R.D. Timmerman,1

**Purpose/Objective(s):** To explore the impact of pre-operative single fraction stereotactic ablative partial breast irradiation (SPBI) dose escalation (30, 34, or 38Gy) on toxicity and tumor response for early-stage hormone receptor (HR)+ breast cancer in an interim analysis of an expanded cohort phase I dose escalation study (NCT04040569).

**Materials/Methods:** Eligible patients (pts) have < 3 cm, HR+, Her2-, cN0 invasive breast carcinomas not requiring chemotherapy. Pts are treated on either MR LINAC, robotic radiosurgery, or cobalt stereotactic breast units. Endocrine therapy is started two weeks after SPBI. Surgery is completed 2-90 days of SPBI. MTD is exceeded if more DLTs occur in any cohort. Limiting toxicity (DLT) is defined as grade ≥3 toxicity or any grade 4/5 toxicity attributed to SPBI. Each dose cohort enrolls 7-15 pts. Dose escalation is permitted if 0/7, 2/9, ≤3/12, or ≤4/15 patients experienced a DLT within 90 days of SPBI. MTD is exceeded if more DLTs occur in any cohort.

<table>
<thead>
<tr>
<th>Year 10</th>
<th>Whole-breast n (%)</th>
<th>Reduced-dose n (%)</th>
<th>Partial-breast n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast shrinkage</td>
<td>None/mild Moderate/ marked</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>290 (91)</td>
<td>293 (91)</td>
<td>307 (94)</td>
</tr>
<tr>
<td>P-value*</td>
<td>0.89</td>
<td>0.30</td>
<td></td>
</tr>
</tbody>
</table>

* P-value compared with whole-breast

Author Disclosure: A. Kirby: Travel expenses; ESTRO Society. Travel costs for ESTRO-related matters covered by ESTRO; European Society of Radiotherapy and Oncology. C. Griffin: Grant/research funding: Accuracy Inc. Compensation/Payment; Institute of Cancer Research MSc in Oncology. L. Finneran: None. M. Sydenham: None. A. Alhasso: None. A. Brutn: None. H. Chan: Board member; Federation of Independent Practitioners. M. Jef ford: None. E. Sawyer: Grant/research funding; Pfizer, Seagen. I. Syndikus: Honoraria; Bayer, Jansen. Travel expenses; Bayer, Jansen. Y. Tsang: Faculty; University of Toronto. Committee Chair; ESTRO. D. Wheatley: None. J. Yarnold: retired; retired. C. Coles: Grant/research funding; National Institute of Health & Care Research (NIHR). Director; CRUK RadNet Cambridge. Chair of breast cancer commission; Lancet Breast Cancer Commission. J. Bliss: Grant/research funding; Astra Zeneca, GBG Forschungs GmbH, CRUK, JP Moulton Foundation, NIHR, Eli Lilly and Company Ltd, AstraZeneca UK Ltd, Merk, Sharp and Dohme Ltd, Verastem, Pfizer, PUMA, Kortuc, Lanssen Clig Ltd. Member of the BIG Executive Board; Breast International group (BIG).
**Results:** From 12/2019 to 6/2023, 11 and 15 pts were treated with 30Gy and 34Gy, respectively. Rates of pCR/nCR are 37.5% for 30Gy versus 92.8% for 34Gy (p=0.01). At 30Gy, 8/11 pts (73%) underwent surgery with a median 4.3 (range 2.8-5.9) month interval from SPBI to surgery: 0/8 (0%) had a pCR and 3/8 (37.5%) had a nCR. At dose level 34Gy, 14/15 pts (93%) underwent surgery with a median 7.3 (range 5.9-12) month interval from SPBI to surgery: 6/14 (42.8%) had a pCR while 7/14 (50%) had a nCR. Of the 8 pts with a nCR, 50% had only 1-3mm of residual disease. The mean kI67 for the entire cohort was 12.0% +/- 6.9% at diagnosis and decreased to 1.4 +/- 2.3% at surgery. 13/14 (92.8%) pts with residual disease had a kI67 < 3% after surgery and SPBI. There were 33 acute grade 1; 2 acute grade 2 (breast pain and dermatitis); and 10 late grade 1 [1 grade 2 (breast pain), and 1 grade 3 (slow healing wound) in an uncontrolled diabetic] toxicities.

**Conclusion:** First study to show pre-operative SPBI up to 34Gy in a single fraction was safe and effective for early-stage HR+ breast cancer. Escalating the dose has achieved a dramatic improvement in pCR/nCR (92.8%) suggesting this is an exciting approach for potentially eliminating tumor with radiation/endocrine therapy alone in early stage breast cancer and potentially paving a path towards non-surgical management in selected patients.


**LBA 12**

**Stereotactic Radiosurgery for 1-10 Brain Metastases Averts Whole-Brain Radiotherapy - Results of the CYBER-SPACE Randomized Phase 2 Trial**

R. El Shafei,1,2 D. Bernhardt,3,4 A. Schiele,1 T. Welzel,1 D. Schmitt,1,2 P. Thalmann,1 S. Erdem,1 A. Paul,1 S.J. Hoene,1 K. Lang,1 L. König,1 F. Weykamp,1 S. Adeberg,1,6 A. Lentz-Hommertgen,1 C. Jaekel,1 F. Bozorgmehr,2,4 M. Thomas,2 M. Kieser,1 J. Debub,1 and S. Rieken1-2

1Heidelberg University Hospital, Dept. of Radiation Oncology, Heidelberg, Germany; 2University Medical Center Göttingen (UMG), Dept. of Radiation Oncology, Göttingen, Germany; 3Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; 4Department of Radiation Oncology, Heidelberg University Hospital e-Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; 5Heidelberg University Hospital, Institute of Medical Biometry, Heidelberg, Germany; 6University Medical Center of Giessen and Marburg (UKGM), Dept. of Radiation Oncology, Marburg, Germany; 7Department of Thoracic Oncology, Thoraxklinik and National Center for Tumor diseases (NCT) Heidelberg, Heidelberg University Hospital, Heidelberg, Germany; 8German Center for Lung Research (DZL), Heidelberg, Germany

**Purpose/Objective(s):** Stereotactic Radiosurgery (SRS) is increasingly used as an alternative to whole-brain radiotherapy (WBRT) in the treatment of patients with multiple brain metastases (BM) with the aim of reducing toxicity and improving tumor control. The CYBER-SPACE trial evaluated SRS based on highly sensitive magnetic resonance imaging (MRI) for patients with 1-10 BM with the aim of avoiding or delaying WBRT.

**Materials/Methods:** Eligible patients with 1-10 newly diagnosed BM regardless of histology were randomized 1:1 to receive SRS of all visible lesions based on either SPACE (sampling perfection with application optimized contrasts using different flip angle evolution) or MPRAGE (magnetization-prepared rapid gradient-echo) MRI sequence. If during follow-up new BM occurred, SRS was repeated for those BM. The primary end-point was ineligibility for further SRS. It was defined as the simultaneous new occurrence or progression of more than 10 BM or leptomeningeal disease. Key secondary endpoints were overall survival (OS), safety, quality of life and neurocognitive function.

**Results:** 202 patients were randomized; SPACE n = 99, MPRAGE n = 103. Most common histologies were non-small cell lung cancer (63%), melanoma (16%) and breast cancer (10%). At data cutoff after 24 months, the probability of ineligibility for further SRS (iIFS), considering death as a competing event was 21.7% (95%-CI: 16.1%; 27.9%) in the overall cohort, 23.9% (95%-CI: 15.9%; 32.9%) in the MPRAGE arm and 19.4% (95%-CI: 11.8%; 28.3%) in the SPACE arm. Median time to iIFS was not reached in either arm. There was no significant difference between SPACE and MPRAGE in time to iIFS (p = 0.411). In multivariable Cox-Regression, 5-10 BM (vs. 2-4 BM) on initial MRI were predictive for shorter time to iIFS (HR 3.13, 95%-CI: 1.53; 6.40, p = 0.002). Median OS was 13.1 months (Q1-Q3: 5.2-44) in both groups combined, 10.5 months (Q1-Q3: 5.1-30.4) in the SPACE arm and 15.2 months (Q1-Q3: 5.6-45.0) in the MPRAGE arm, with no significant difference between arms (p = 0.585). In multivariable Cox-Regression, predictors for longer OS were a Karnofsky Performance Status >80% (HR 0.51, 95%-CI: 0.33; 0.77, p = 0.002), concomitant immunotherapy (HR 0.34, 95%-CI: 0.23; 0.52, p < 0.001) or targeted therapy (HR 0.51, 95%-CI: 0.34; 0.78, p = 0.002), however not the initial number of BM. Cause of death was known for 108 of 138 patients (78.3%). 14 patients (10.1%) died from BM, 94 patients (68.1%) from extracranial causes.

**Conclusion:** SRS for patients with 1-10 BM avoided the need for WBRT in 79.2% of cases, when repeated upon occurrence of new lesions. Regular high-sensitivity MRI is a prerequisite for this strategy. Proactive management of multiple BM with SRS can greatly limit the impact of BM on overall prognosis.


**LBA 13**

**Hypofractionated Stereotactic Radiotherapy (HFSRT) of the Resection Cavity vs. Whole-Brain Radiotherapy (WBRT) Following Brain Metastasis Resection – Results of the ESTRON Randomized Phase 2 Trial**

R. El Shafei,1,2 D. Bernhardt,3,4 A. Schiele,1 T. Welzel,1 D. Schmitt,1,2 P. Thalmann,1 S. Erdem,1 A. Paul,1 S.J. Hoene,1 K. Lang,1 L. König,1 F. Weykamp,1 S. Adeberg,1,2 A. Lentz-Hommertgen,1 C. Jaekel,1 F. Bozorgmehr,2,4 M. Thomas,2 M. Kieser,1 J. Debub,1 and S. Rieken1,2

1University Medical Center Göttingen (UMG), Dept. of Radiation Oncology, Göttingen, Germany; 2Heidelberg University Hospital, Dept. of Radiation Oncology, Heidelberg, Germany; 3Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany; 4Department of Radiation Oncology, Heidelberg University Hospital.
Purpose/Objective(s): Radiotherapy of the resection cavity following brain metastasis (BM) resection improves local control. Single-session stereotactic radiosurgery (SRS) can reduce toxicity compared to whole-brain radiotherapy (WBRT). Hypofractionated stereotactic radiotherapy (HSRT) can deliver a higher biologically effective dose, potentially improving local control over SRS. The ESTRON trial compared HFSRT of the cavity with post-operative WBRT in patients with 1-10 BM.

Materials/Methods: Eligible patients with 1-10 newly diagnosed BM and following the resection of one BM regardless of histology were randomized 1:1 to receive HFSRT of the cavity and SRS of all unresected lesions or WBRT. A dose of 7 × 5 Gy was delivered to the cavity with a safety margin of 3-4 mm based on highly sensitive and standardized magnetic resonance imaging (MRI). The primary endpoint was intracranial control. Key secondary endpoints were overall survival (OS), safety, quality of life and neurocognitive function.

Results: 54 patients were randomized; HFSRT n=27, WBRT n=27. Most common histologies were non-small cell lung cancer (54%) and breast cancer (13%). Median diameter was 28 mm (Q1-Q3: 22-33). 27 patients (52%) had at least one and 14 patients (26%) had >3 unresected BM. 15 patients (29%) had residual tumor at the cavity. These characteristics did not significantly affect survival. At 12 months, intracranial control (IC) was 44% in the HFSRT and 59% in the WBRT arm. Median intracranial progression-free survival was 4.7 months (Q1-Q3: 1.7-18.0) in the HFSRT arm and 15.2 months (Q1-Q3: 5.6-12.7) in the WBRT arm (HR 1.72, 95%-CI: 0.94; 3.17, p = 0.080). In multivariable Cox-Regression, incomplete resection was predictive of inferior IC (HR 2.18, 95%-CI: 0.99; 4.79, p = 0.052). 3-year Local control (LC) at the cavity was 96% in the HFSRT arm and 89% in the WBRT arm (p=0.116) with a median follow-up of 19.7 months. Progression occurred distant from the cavity in 96% of cases (n = 26 out of 27). Leptomeningeal disease (LD) occurred in 7 patients (26%) in the HFSRT arm and 2 patients (7%) in the WBRT arm. LD occurred out of field in 6/7 cases in the HFSRT arm. 4 patients (15%) in the HFSRT arm and none in the WBRT arm developed blood brain barrier disruption at the cavity; 2 of those were symptomatic requiring treatment. Median OS was 10.3 months (Q1-Q3: 3.7-19.5) in the HFSRT arm and 18.6 months (Q1-Q3: 7.2-26.6) in the WBRT arm (HR 1.38, 95%-CI: 0.72; 2.66, p = 0.336).

Conclusion: Following the resection of BM, HFSRT of the resection cavity provides excellent local control. Compared to WBRT, distant intracranial progression and LD remain a relevant risk and rigorous follow-up is warranted. Detailed analyses on neurocognitive function are pending.
